
Infarct Size Alone Doesn't Predict Thrombectomy Outcomes, Registry Shows
Key Takeaways
- Baseline imbalances were substantial: large-core patients had higher NIHSS, worse collaterals, less IV-tPA, and longer onset-to-deployment times than moderate-core patients.
- Unadjusted outcomes favored moderate-core for 90-day mRS 0–2/no worsening, while 90-day all-cause mortality was not significantly different between core-size strata.
A real-world registry found that large infarct core size does not independently predict worse functional or safety outcomes after thrombectomy, compared with moderate-core infarcts.
At the
Yazan K. Ashouri, MD, of Mercy Health St. Vincent Medical Center, led the post-hoc analysis of the EXCELLENT registry (NCT03685578), which tracks outcomes in patients treated with the EmboTrap thrombectomy device.1,2 The analysis included 686 patients with anterior circulation internal carotid artery, M1, or M2 occlusions and a baseline Alberta Stroke Program Early CT Score (ASPECTS) of 0 to 7, independently assessed by a core imaging laboratory. Patients were stratified into a large-core group (ASPECTS 0-5, n=219) and a moderate-core group (ASPECTS 6-7, n=467).
The large-core group presented with more severe strokes at baseline, with a median National Institutes of Health Stroke Scale (NIHSS) score of 18.0 versus 16.0 in the moderate-core group. Large-core patients also received intravenous tissue plasminogen activator (IV-tPA) less often (16.9% vs 32.5%), had worse angiographic collateral circulation, and waited longer for treatment, with a median 7.10 hours from stroke onset to first device deployment versus 5.42 hours in the moderate-core group.
In unadjusted comparisons, moderate-core patients were more likely than large-core patients to reach the primary functional outcome, a 90-day modified Rankin Scale (mRS) score of 0 to 2 or no worsening from baseline (43.2% vs 26.9%; P<.001), and 90-day all-cause mortality did not differ significantly between groups (18.6% vs 22.6%; P =.232).1
After multivariable adjustment, however, large-core status no longer independently predicted either outcome. The adjusted odds ratio (OR) for large-core versus moderate-core infarct was 0.786 for the functional outcome (95% CI, 0.483-1.279; P =.333) and 0.951 for mortality (95% CI, 0.581-1.557; P =.843). Each additional hour from stroke onset to device deployment, by contrast, independently lowered the odds of a good functional outcome by about 7% (OR, 0.931; 95% CI, 0.889-0.974; P =.002), though it was not associated with mortality (OR, 1.002; 95% CI, 0.963-1.043; P =.913).
Other factors independently associated with worse functional outcome included older age, diabetes, higher baseline NIHSS, and more than 3 thrombectomy device passes, while older age, chronic obstructive pulmonary disease, a hypercoagulable state, higher baseline NIHSS, and a pre-stroke mRS of 3 to 5 each independently predicted higher mortality; IV-tPA use was independently associated with lower mortality.
Building on the pivotal large-core thrombectomy trials
The EXCELLENT analysis extends evidence from the randomized trials that established thrombectomy as a treatment option in selected patients with large infarct cores,
Those trials established that appropriately selected large-core patients can benefit from thrombectomy, but the EXCELLENT investigators noted that real-world evidence outside the controlled trial setting remained limited.1 Because EXCELLENT is a prospective, multicenter registry built around a single thrombectomy device rather than a randomized comparison, its findings reflect a specific real-world population and treatment approach rather than a head-to-head trial of core size itself.2
The authors concluded that in this real-world registry population, large-core infarct status alone was not an independent predictor of functional or safety outcomes relative to moderate-core infarct, but faster time to device deployment was significantly associated with better clinical outcomes. They said the findings suggest treatment speed may influence outcomes in large-core stroke more than infarct size alone, supporting continued consideration of thrombectomy in carefully selected large-core patients.1
For more SVIN 2026 coverage,
References
1. Ashouri YK, Andersson T, Siddiqui AH, et al. Real-world outcomes after thrombectomy for large-core versus moderate-core anterior circulation stroke: subgroup analysis from the EXCELLENT registry. Presented at: 2026 Society of Vascular and Interventional Neurology Annual Meeting; November 17-20, 2026; Las Vegas, NV.
2. Siddiqui AH, Waqas M, Brinjikji W, et al. Embotrap Extraction and Clot Evaluation and Lesion Evaluation for NeuroThrombectomy (EXCELLENT) Registry design and methods. J Neurointerv Surg. 2022;14(8):783-787. doi:10.1136/neurintsurg-2021-017671
3. Sarraj A, Hassan AE, Abraham MG, et al. Trial of endovascular thrombectomy for large ischemic strokes. N Engl J Med. 2023;388(14):1259-1271. doi:10.1056/NEJMoa2214403
4. Huo X, Ma G, Tong X, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct. N Engl J Med. 2023;388(14):1272-1283. doi:10.1056/NEJMoa2213379
Related to this article








